Arch Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTH research report →
Price Chart
About the company
Arch Therapeutics, Inc. , operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform.
- CEO
- Terrence W. Norchi
- IPO
- 2013
- Employees
- 8
- HQ
- Framingham, MA, US
Get TickerSpark's AI analysis on ARTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $444
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -1.39
- Div Yield
- 0.00%
- Gross Margin
- -3.22%
- Op Margin
- -6661.67%
- Net Margin
- -9221.43%
- ROE
- 119.36%
- ROIC
- 268.33%
Latest fiscal year · YoY change
- Revenue
- $75.72K+383.8%
- Gross Profit
- $-2,439+93.2%
- Op Income
- $-5,044,483
- Net Income
- $-6,982,836-63.3%
- EPS
- $-2.27+36.2%
- OCF Growth
- +24.3%
- FCF Growth
- +24.2%
- 52W High
- $1.57
- 52W Low
- $0.00
- 50D MA
- $0.18
- 200D MA
- $0.32
- Beta
- 4.03
- RSI (14)
- 20
- Avg Volume
- 2.12K
No earnings-call transcripts are available for ARTH yet.
- Free Float
- 96.7%
- Shares Outstanding
- 4.44M
- Float Shares
- 4.30M
of shares held by institutions
3 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 23 | ABRAMS MICHAEL S | other | 20,584 |
| Aug 31, 23 | ABRAMS MICHAEL S | buy | 10,292 |
| Aug 31, 23 | Norchi Terrence W | other | 13,724 |
| Aug 31, 23 | Norchi Terrence W | buy | 6,862 |
| Aug 31, 23 | Hicks Laurence | other | 20,584 |
| Aug 31, 23 | Hicks Laurence | buy | 10,292 |
| Nov 10, 22 | DHILLON PUNIT | other | 250,000 |
| Nov 10, 22 | Fish Guy L. | other | 250,000 |
| Nov 10, 22 | Hicks Laurence | other | 250,000 |
| Nov 10, 22 | Yrigoyen Dan | other | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARTH coverage
Recent articles, reports, and earnings notes.
No research on ARTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARTH report →SANUWAVE Health (OTCMKTS:SNWV) and Arch Therapeutics (OTCMKTS:ARTH) Critical Review
defenseworld.net · Feb 1
Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
defenseworld.net · Dec 5
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
globenewswire.com · Oct 1
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
globenewswire.com · May 6
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
zacks.com · Dec 27
7 Stock Winners That Are Up 1,000% or More in 2023
investorplace.com · Dec 12
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
zacks.com · Dec 11
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
zacks.com · Nov 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.